1. Home
  2. TREE vs CTNM Comparison

TREE vs CTNM Comparison

Compare TREE & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LendingTree Inc.

TREE

LendingTree Inc.

HOLD

Current Price

$26.05

Market Cap

376.5M

Sector

Finance

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$13.47

Market Cap

550.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TREE
CTNM
Founded
1996
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
376.5M
550.7M
IPO Year
2008
2024

Fundamental Metrics

Financial Performance
Metric
TREE
CTNM
Price
$26.05
$13.47
Analyst Decision
Strong Buy
Buy
Analyst Count
4
4
Target Price
$71.25
$19.00
AVG Volume (30 Days)
386.4K
431.9K
Earning Date
04-30-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
443.31
0.46
EPS
1.90
N/A
Revenue
$1,117,324,000.00
N/A
Revenue This Year
$19.03
N/A
Revenue Next Year
$7.07
N/A
P/E Ratio
$14.19
N/A
Revenue Growth
24.12
N/A
52 Week Low
$25.56
$8.60
52 Week High
$71.17
$17.79

Technical Indicators

Market Signals
Indicator
TREE
CTNM
Relative Strength Index (RSI) 34.75 38.32
Support Level N/A $13.65
Resistance Level $39.74 $15.36
Average True Range (ATR) 1.09 0.86
MACD 0.19 -0.30
Stochastic Oscillator 10.76 17.66

Price Performance

Historical Comparison
TREE
CTNM

About TREE LendingTree Inc.

LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: